Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 17,818 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Dose level 3 Clear all

Conditions: Crohn Disease
Interventions: Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Mycophenolic Acid, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Stress Disorders, Post-Traumatic, Bulimia Nervosa
Interventions: Prazosin, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Advanced Cancer, Advanced Solid Tumor, Cancer
Interventions: STC-15; Drug
Lead sponsor: STORM Therapeutics LTD; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Houston, Texas • San Antonio, Texas

Conditions: Psychiatric Disorders
Interventions: KarXT, KarX-EC; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 4
States / cities: Little Rock, Arkansas • Orange, California • Decatur, Georgia + 1 more

Conditions: Anal Dysplasia, Carcinoma in Situ
Interventions: Gliolan, Vitamin D3 cholecalciferol), Photodynamic Therpay; Drug · Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Periodontal Disease
Interventions: ST266, Saline (0.9% NaCl); Biological · Drug
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more

Conditions: Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Interventions: ADRX-0706; Drug
Lead sponsor: Adcentrx Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Los Angeles, California • St. Petersburg, Florida • Tampa, Florida + 8 more

Conditions: Advanced Solid Tumors
Interventions: YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin); Drug
Lead sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Aurora, Colorado • Denver, Colorado • North Haven, Connecticut + 7 more

Conditions: Down Syndrome, Cognitive Dysfunction
Interventions: Aricept (donepezil hydrochloride), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: San Antonio, Texas • Herndon, Virginia

Conditions: Endometrial Neoplasms
Interventions: Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 827 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 25
States / cities: Phoenix, Arizona • San Francisco, California • Santa Monica, California + 22 more

Conditions: Healthy
Interventions: Maraviroc, Fosamprenavir, Ritonavir; Drug
Lead sponsor: Garden State Infectious Disease Associates, PA; Other
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: Herpes Simplex Virus
Interventions: Novel Antiviral Drug, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 98 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more

Conditions: Excessive Sleepiness
Interventions: Armodafinil, Matching Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more

Conditions: Gastroparesis
Interventions: GSK962040 50 mg, Metoclopramide 10 mg, Placebo NG, Placebo IV; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Aurora, Colorado • Augusta, Georgia • Louisville, Kentucky + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: KD026, Placebo, Metformin; Drug
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • West Hills, California + 6 more

Conditions: Hypoparathyroidism
Interventions: 25mcg rhPTH(1-84), 50mcg rhPTH(1-84), 100mcg rhPTH(1-84); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: North Hollywood, California • Indianapolis, Indiana • Lexington, Kentucky + 7 more

Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma
Interventions: Glofitamab; Biological
Lead sponsor: Joshua Brody; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid-use Disorder, Opioid-Related Disorders
Interventions: Open-Label Placebo (OLP); Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: Bifeprunox, Quetiapine; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 69
States / cities: Anaheim, California • Cerritos, California • Costa Mesa, California + 52 more

Conditions: Opioid Use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Oakland, California • San Leandro, California • Portland, Maine + 2 more

Conditions: Fragile x Syndrome
Interventions: Ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
Interventions: Doxorubicin Hydrochloride, Gemcitabine Hydrochloride, Ixazomib Citrate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: DIRA
Interventions: Rilonacept; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 3 Months and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions: Donor CD34+, CD3+. and belumosudil; Combination Product
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Crohn's Allogeneic Transplant Study

Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD

Oral Administration of STC-15 in Subjects With Advanced Malignancies

Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

PDT Plus Vitamin D3 for Anal Dysplasia

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

A Study of ADRX-0706 in Select Advanced Solid Tumors

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism

Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

Harnessing Placebo Effects in Methadone Treatment

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

Standard Versus High Dose ED-Initiated Buprenorphine Induction

Ganaxolone Treatment in Children With Fragile X Syndrome

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)

Immunological Tolerance in Patients With Mismatched Kidney Transplants